ArticleClinical and experimental immunology2016
Interleukin 10 and dendritic cells are the main suppression mediators of regulatory T cells in human neurocysticercosis.
Article in Clinical and experimental immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- The TPx protein ofFrontiers in immunology · 2026Article
- Adrenergic signaling during parasitic infections.Frontiers in immunology · 2025Review
- Innate Immune Response to Helminth Infections.Advances in experimental medicine and biology · 2025Review
- Immunologic Profiling of CSF in Subarachnoid Neurocysticercosis Reveals Specific Interleukin-10-Producing Cell Populations During Treatment.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Regulatory T cells modulate monocyte functions in immunocompetent antiretroviral therapy naive HIV-1 infected people.BMC immunology · 2024Article
- Increased levels of regulatory T cells and IL-10-producing regulatory B cells are linked to improved clinical outcome in Parkinson's disease: a 1-year observational study.Journal of neural transmission (Vienna, Austria : 1996) · 2024Observational
- Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?Pathogens (Basel, Switzerland) · 2023Article
- Standardizing an Experimental Murine Model of Extraparenchymal Neurocysticercosis That Immunologically Resembles Human Infection.Brain sciences · 2023Article
- Low responsiveness of peripheral lymphocytes in extraparenchymal neurocysticercosis.PLoS neglected tropical diseases · 2023Article
- IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis.Journal of experimental & clinical cancer research : CR · 2022Article
- Helminthic dehydrogenase drives PGEEMBO reports · 2022Article
- The Local Inflammatory Profile and Predictors of Treatment Success in Subarachnoid Neurocysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Article
- Chronic administration of cryptolepine nanoparticle formulation alleviates seizures in a neurocysticercosis model.Current research in pharmacology and drug discovery · 2021Article
- Regulatory T Cells as an Escape Mechanism to the Immune Response inFrontiers in cellular and infection microbiology · 2021Article
- Taenia solium Cysticercosis and Its Impact in Neurological Disease.Clinical microbiology reviews · 2020Review
- Host immune responses during Taenia solium Neurocysticercosis infection and treatment.PLoS neglected tropical diseases · 2020Review
- Regulatory impairment in untreated Parkinson's disease is not restricted to Tregs: other regulatory populations are also involved.Journal of neuroinflammation · 2019Article
- Neurocysticercosis in Pregnancy.AJP reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurocysticercosis is caused by the establishment of Taenia solium cysticerci in the central nervous system. It is considered that, during co-evolution, the parasite developed strategies to modulate the host's immune response. The action mechanisms of regulatory T cells in controlling the immune response in neurocysticercosis are studied in this work. Higher blood levels of regulatory T cells with CD4(+) CD45RO(+) forkhead box protein 3 (FoxP3)(high) and CD4(+) CD25(high) FoxP3(+) CD95(high) phenotype and of non-regulatory CD4(+) CD45RO(+) FoxP3(med) T cells were found in neurocysticercosis patients with respect to controls. Interestingly, regulatory T cells express higher levels of cytotoxic T lymphocyte antigen 4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), programmed death 1 (PD-1) and glucocorticoid-induced tumour necrosis factor receptor (GITR), suggesting a cell-to-cell contact mechanism with dendritic cells. Furthermore, higher IL-10 and regulatory T cell type 1 (Tr1) levels were found in neurocysticercosis patients' peripheral blood, suggesting that the action mechanism of regulatory T cells involves the release of immunomodulatory cytokines. No evidence was found of the regulatory T cell role in inhibiting the proliferative response. Suppressive regulatory T cells from neurocysticercosis patients correlated negatively with late activated lymphocytes (CD4(+) CD38(+) ). Our results suggest that, during neurocysticercosis, regulatory T cells could control the immune response, probably by a cell-to-cell contact with dendritic cells and interleukin (IL)-10 release by Tr1, to create an immunomodulatory environment that may favour the development of T. solium cysticerci and their permanence in the central nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.